Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 21, 2013; 19(7): 1111-1118
Published online Feb 21, 2013. doi: 10.3748/wjg.v19.i7.1111
Figure 1
Figure 1 Diagram showing the study enrollment.
Figure 2
Figure 2 Survival curve of all patients in this cohort.
Figure 3
Figure 3 Cumulative rates of decompensation-free disease in primary biliary cirrhosis patients stratified by ursodeoxycholic acid treatment, anti-centromere antibody, and histological stage, respectively. A: Ursodeoxycholic acid (UDCA); B: Anti-centromere antibody (ACA); C: Histological stage.